Journal of Neurology

, Volume 253, Supplement 4, pp iv16–iv21

Clinical studies with ropinirole in Parkinson’s disease and RLS

  • Wolfgang H. Jost
  • Dieter Angersbach
  • Olivier Rascol
Article

DOI: 10.1007/s00415-006-4004-4

Cite this article as:
Jost, W.H., Angersbach, D. & Rascol, O. J Neurol (2006) 253(Suppl 4): iv16. doi:10.1007/s00415-006-4004-4
  • 71 Downloads

Abstract

Ropinirole is a modern dopamine agonist with a halflife of medium extent that is highly selective for D2-receptors. Ropinirole is an indole derivative and thus does not belong to the group of ergoline dopamine receptor agonists. Its effect has been proved in a number of controlled studies in both monotherapy and combination treatments of Parkinson’s disease. We can meanwhile refer to the long-term data of studies that have been run for more than 10 years. The substance has also been approved for the management of restless legs syndrome. A long-acting formula of the substance will be available soon.

Key words

Parkinson’s diseaseropiniroledopamine agonists

Copyright information

© Steinkopff-Verlag 2006

Authors and Affiliations

  • Wolfgang H. Jost
    • 1
  • Dieter Angersbach
    • 2
  • Olivier Rascol
    • 3
  1. 1.Dept. NeurologyDeutsche Klinik für DiagnostikWiesbadenGermany
  2. 2.GlaxoSmithKlineMunichGermany
  3. 3.Depts. of Clinical Pharmacology and NeurosciencesToulouse University HospitalToulouseFrance